trending Market Intelligence /marketintelligence/en/news-insights/trending/hh6xwhw9gmciyrupunzsoa2 content esgSubNav
In This List

Xenon Pharmaceuticals names president, chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Xenon Pharmaceuticals names president, chief medical officer

Xenon Pharmaceuticals Inc. promoted Ian Mortimer to president in addition to his current role as CFO.

In addition, the company appointed Ernesto Aycardi as chief medical officer, effective March 19.

Aycardi worked from 2014 to 2018 at Teva Pharmaceutical Industries Ltd., where he most recently served as vice president and head of clinical trial operations, biostatistics and data sciences and clinical pharmacology.

Canada-based Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders.